Cami S. Sima

1.7k total citations · 1 hit paper
12 papers, 1.3k citations indexed

About

Cami S. Sima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Cami S. Sima has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Surgery. Recurrent topics in Cami S. Sima's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Cami S. Sima is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Cami S. Sima collaborates with scholars based in United States, Switzerland and Canada. Cami S. Sima's co-authors include Mark G. Kris, Gregory J. Riely, Akihiko Yoshizawa, Noriko Motoi, Valerie W. Rusch, William D. Travis, William L. Gerald, Bernard J. Park, Robert W. Haile and Patrick Concannon and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Cami S. Sima

11 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

2011 757 citations Akihiko Yoshizawa, Noriko Motoi et al. Modern Pathology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cami S. Sima United States	7	847	464	242	238	220	12	1.3k
Michael Kolinsky Canada	13	572 0.7×	361 0.8×	182 0.8×	168 0.7×	197 0.9×	54	824
Daygen L. Finch Canada	15	880 1.0×	447 1.0×	335 1.4×	194 0.8×	444 2.0×	36	1.2k
Joseph J. Stephenson United States	8	340 0.4×	426 0.9×	275 1.1×	56 0.2×	326 1.5×	13	888
A. Ashworth Canada	13	593 0.7×	554 1.2×	248 1.0×	118 0.5×	278 1.3×	26	1.2k
Zafeiris Zafeiriou United Kingdom	13	536 0.6×	422 0.9×	158 0.7×	172 0.7×	345 1.6×	31	873
Hidehiko Shimokawa Japan	17	570 0.7×	435 0.9×	291 1.2×	95 0.4×	155 0.7×	53	971
Miriam Hatsue Honda Federico Brazil	13	484 0.6×	478 1.0×	196 0.8×	94 0.4×	190 0.9×	17	851
Alejo Rodríguez‐Vida Spain	18	686 0.8×	484 1.0×	359 1.5×	223 0.9×	263 1.2×	95	1.1k
Włodzimierz Olszewski Poland	19	492 0.6×	476 1.0×	289 1.2×	74 0.3×	409 1.9×	51	1.1k
Hamid Emamekhoo United States	16	446 0.5×	412 0.9×	404 1.7×	66 0.3×	162 0.7×	96	961

Countries citing papers authored by Cami S. Sima

Since Specialization

Citations

This map shows the geographic impact of Cami S. Sima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cami S. Sima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cami S. Sima more than expected).

Fields of papers citing papers by Cami S. Sima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cami S. Sima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cami S. Sima. The network helps show where Cami S. Sima may publish in the future.

Co-authorship network of co-authors of Cami S. Sima

This figure shows the co-authorship network connecting the top 25 collaborators of Cami S. Sima. A scholar is included among the top collaborators of Cami S. Sima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cami S. Sima. Cami S. Sima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Germini, Federico, Man‐Chiu Poon, Arun Keepanasseril, et al.. (2020). Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 136(Supplement 1). 37–38. 1 indexed citations

Sherman, Eric J., Lara Dunn, Heiko Schöder, et al.. (2019). Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer. 125(17). 2984–2990. 6 indexed citations

Chang, Tiffany, et al.. (2019). Estimating the Risk of Myocardial Infarction in Persons with Hemophilia A Using a Machine-Learning Approach with US Claims Data. Blood. 134(Supplement_1). 1133–1133. 5 indexed citations

Sherman, Eric J., Lara Dunn, Alan L. Ho, et al.. (2017). Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer. Cancer. 123(21). 4114–4121. 56 indexed citations

Drilon, Alexander, Isabella Bergagnini, Lukas Delasos, et al.. (2016). Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of Oncology. 27(7). 1286–1291. 87 indexed citations

Yu, Helena A., Cami S. Sima, Darren R. Feldman, et al.. (2016). Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of Oncology. 28(2). 278–284. 44 indexed citations

Ho, Alan L., Lara Dunn, Eric J. Sherman, et al.. (2016). A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Annals of Oncology. 27(10). 1902–1908. 85 indexed citations

Pietanza, M. Catherine, Anya M. Litvak, Anna M. Varghese, et al.. (2016). A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung Cancer. 99. 23–30. 55 indexed citations

Yoshizawa, Akihiko, Noriko Motoi, Gregory J. Riely, et al.. (2011). Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology. 24(5). 653–664. 757 indexed citations breakdown →

10.

Sima, Cami S., Katherine S. Panageas, Glenn Heller, & Deborah Schrag. (2010). Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Applied Health Economics and Health Policy. 8(1). 37–51. 2 indexed citations

11.

Lou, Emil, Cami S. Sima, Rita Gonzalez-Espinoza, et al.. (2010). Analysis of a panel of serum biomarkers in patients with metastatic lung cancer.. Journal of Clinical Oncology. 28(15_suppl). e18080–e18080. 1 indexed citations

12.

Begg, Colin B., Robert W. Haile, Åke Borg, et al.. (2008). Variation of Breast Cancer Risk Among BRCA1/2 Carriers. JAMA. 299(2). 194–201. 187 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact